Relling Mary V, Evans William E
Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee 38105-2794, USA.
Nature. 2015 Oct 15;526(7573):343-50. doi: 10.1038/nature15817.
After decades of discovery, inherited variations have been identified in approximately 20 genes that affect about 80 medications and are actionable in the clinic. And some somatically acquired genetic variants direct the choice of 'targeted' anticancer drugs for individual patients. Current efforts that focus on the processes required to appropriately act on pharmacogenomic variability in the clinic are moving away from discovery and towards implementation of an evidenced-based strategy for improving the use of medications, thereby providing a cornerstone for precision medicine.
经过数十年的探索,已在约20个基因中鉴定出遗传性变异,这些变异影响约80种药物,且在临床上具有可操作性。一些体细胞获得性基因变异指导着针对个体患者的“靶向”抗癌药物的选择。目前专注于在临床上对药物基因组变异采取适当行动所需过程的努力,正从发现阶段转向实施基于证据的策略以改善药物使用,从而为精准医学奠定基石。